Related Experiment Video

Updated: Mar 21, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

Yogesh A Sonawane1, Margaret A Taylor1, John Victor Napoleon1

  • 1Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center , Omaha, Nebraska 68198-6805, United States.

Journal of Medicinal Chemistry
|May 13, 2016
PubMed

Insights

Cyclin-dependent kinase 9 (CDK9) inhibitors are promising cancer therapeutics. This review covers CDK9 regulation, functions, and targeted inhibitor structures, selectivity, and efficacy.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • Cyclin-dependent kinases (CDKs) are crucial cell regulators, with CDK9 emerging as a key target in cancer therapy.
  • CDK9 regulates transcription, particularly of antiapoptotic proteins essential for cancer cell survival.
  • Developing selective CDK9 inhibitors has faced challenges due to diverse CDK functions.

Purpose of the Study:

  • To review the regulation and cellular functions of CDK9.
  • To analyze common structural scaffolds for CDK9 inhibitors.
  • To evaluate the selectivity and efficacy of CDK9 inhibitors in preclinical models.

Main Methods:

  • Literature review of CDK9 regulation and function.
  • Analysis of chemical libraries and reported CDK9 inhibitors.
  • Examination of in vitro and in vivo efficacy data for CDK9 inhibitors.

Main Results:

  • CDK9's critical role in regulating short-lived antiapoptotic proteins highlights its importance in cancer.
  • Various chemical scaffolds have been explored for CDK9 inhibition with varying success.
  • Selectivity and efficacy profiles differ significantly across identified CDK9 inhibitors.

Conclusions:

  • CDK9 is a validated druggable target for cancer therapy.
  • Further development of selective CDK9 inhibitors is warranted.
  • Understanding inhibitor selectivity and efficacy is crucial for therapeutic advancement.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.4K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K